The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia

A Nationwide Population-Based Nested Case-Control Study
Published:August 04, 2017DOI:https://doi.org/10.1016/j.chest.2017.07.030

      Background

      The relationship between the use of benzodiazepine-receptor agonists (BZRAs) and the risk of hospitalization for pneumonia remains inconclusive. This study aimed to explore the association between BZRA use and hospitalization for pneumonia in a general population.

      Methods

      This population-based nested case-control study used Taiwan’s National Health Insurance Research Database between 2002 and 2012. We included only new users who did not have any BZRA prescriptions on record in the preceding 2 years and identified 12,002 subjects who were hospitalized for pneumonia (International Classification of Diseases, Ninth Revision codes 480-486, and 507) and 12,002 disease risk score-matched control subjects. A logistic regression model was used to determine the association of BZRA use and hospitalization for pneumonia. The exposure date, dose-response relationship, and class of BZRAs were comprehensively assessed.

      Results

      Current BZRA exposure was associated with hospitalization for pneumonia (adjusted OR [aOR],1.86; 95% CI, 1.75-1.97). Benzodiazepine hypnotic agents (aOR, 2.42; 95% CI, 2.16-2.71) had a higher risk of pneumonia than did benzodiazepine anxiolytic agents (aOR, 1.53; 95% CI, 1.44-1.63) or nonbenzodiazepine hypnotic agents (aOR, 1.60; 95% CI, 1.46-1.76). The pneumonia risk was increased with ultrashort-acting and short- to intermediate-acting agents, a higher defined daily dose, and the number of BZRAs used. Among individual BZRAs examined, midazolam had a higher risk (aOR, 5.77; 95% CI, 4.31-7.73) of hospitalization for pneumonia than did the others.

      Conclusions

      This study suggests that there is a dose-response relationship between current BZRA use and the risk of hospitalization for pneumonia. In addition, benzodiazepine hypnotic agents, especially midazolam, present a greater risk of hospitalization for pneumonia. These findings reinforce the importance of a careful analysis of the benefits vs the risks of BZRA use.

      Key Words

      Abbreviations:

      ATC ( Anatomical Therapeutic Chemical), BZRA ( benzodiazepine-receptor agonist), CCI ( Charlson comorbidity index), DDD ( defined daily dose), ICD ( International Classification of Diseases), NHI ( National Health Insurance), NHIRD ( National Health Insurance Research Database)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Donoghue J.
        • Lader M.
        Usage of benzodiazepines: a review.
        Int J Psychiatry Clin Pract. 2010; 14: 78-87
        • Ohayon M.M.
        • Lader M.H.
        Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom.
        J Clin Psychiatry. 2002; 63: 817-825
        • Olfson M.
        • King M.
        • Schoenbaum M.
        Benzodiazepine use in the United States.
        JAMA Psychiatry. 2015; 72: 136-142
        • Wang L.J.
        • Chen Y.C.
        • Chen C.K.
        • Chou W.J.
        • Chou M.C.
        Trends in anxiolytic-hypnotic use and polypharmacy in Taiwan, 2002-2009: a nationwide, population-based survey.
        Psychiatr Serv. 2014; 65: 208-214
        • Huang W.S.
        • Muo C.H.
        • Chang S.N.
        • Chang Y.J.
        • Tsai C.H.
        • Kao C.H.
        Benzodiazepine use and risk of stroke: a retrospective population-based cohort study.
        Psychiatry Clin Neurosci. 2014; 68: 255-262
        • Billioti de Gage S.
        • Moride Y.
        • Ducruet T.
        • et al.
        Benzodiazepine use and risk of Alzheimer's disease: case-control study.
        BMJ. 2014; 349: g5205
        • Weich S.
        • Pearce H.L.
        • Croft P.
        • et al.
        Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study.
        BMJ. 2014; 348: g1996
        • Holbrook A.M.
        • Crowther R.
        • Lotter A.
        • Cheng C.
        • King D.
        Meta-analysis of benzodiazepine use in the treatment of insomnia.
        CMAJ. 2000; 162: 225-233
        • Rushnak M.J.
        • Leevy C.M.
        Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study.
        Am J Gastroenterol. 1980; 73: 127-130
        • Sanders R.D.
        • Godlee A.
        • Fujimori T.
        • et al.
        Benzodiazepine augmented gamma-amino-butyric acid signaling increases mortality from pneumonia in mice.
        Crit Care Med. 2013; 41: 1627-1636
        • Liu C.L.
        • Shau W.Y.
        • Chang C.H.
        • Wu C.S.
        • Lai M.S.
        Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
        J Epidemiol. 2013; 23: 344-350
        • Danaei G.
        • Tavakkoli M.
        • Hernan M.A.
        Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.
        Am J Epidemiol. 2012; 175: 250-262
        • Su V.Y.
        • Liu C.J.
        • Wang H.K.
        • et al.
        Sleep apnea and risk of pneumonia: a nationwide population-based study.
        CMAJ. 2014; 186: 415-421
        • WHO Collaborating Centre for Drug Statistic Methodology
        Guidelines for ATC Classification and DDD Assignment.
        World Health Organization, Oslo2012
        • Schneeweiss S.
        • Maclure M.
        Use of comorbidity scores for control of confounding in studies using administrative databases.
        Int J Epidemiol. 2000; 29: 891-898
        • Greenblatt D.J.
        • Shader R.I.
        • Divoll M.
        • Harmatz J.S.
        Benzodiazepines: a summary of pharmacokinetic properties.
        Br J Clin Pharmacol. 1981; 11: 11S-16S
        • Greenblatt D.J.
        • Divoll M.
        • Abernethy D.R.
        • Ochs H.R.
        • Shader R.I.
        Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.
        Drug Metab Rev. 1983; 14: 251-292
        • Monti J.M.
        • Monti D.
        Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics.
        in: Pandi-Perumal S.R. Monti J.M. Clinical Pharmacology of Sleep. Birkhauser Verlag, Basel (CH)2006: 207-223
        • Arbogast P.G.
        • Ray W.A.
        Use of disease risk scores in pharmacoepidemiologic studies.
        Stat Methods Med Res. 2009; 18: 67-80
        • Wyss R.
        • Ellis A.R.
        • Brookhart M.A.
        • et al.
        Matching on the disease risk score in comparative effectiveness research of new treatments.
        Pharmacoepidemiol Drug Saf. 2015; 24: 951-961
        • Obiora E.
        • Hubbard R.
        • Sanders R.D.
        • Myles P.R.
        The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort.
        Thorax. 2013; 68: 163-170
        • Nakafero G.
        • Sanders R.D.
        • Nguyen-Van-Tam J.S.
        • Myles P.R.
        The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK primary care data.
        Pharmacoepidemiol Drug Saf. 2016; 25: 1263-1273
        • Vozoris N.T.
        • Fischer H.D.
        • Wang X.
        • et al.
        Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD.
        Eur Respir J. 2014; 44: 332-340
        • Jung S.
        • Spence M.M.
        • Escasa N.M.
        • Lee E.A.
        • Hui R.L.
        • Gibbs N.E.
        The risk of pneumonia in older adults using nonbenzodiazepine hypnotics.
        J Manag Care Spec Pharm. 2016; 22: 932-938
        • Dublin S.
        • Walker R.L.
        • Jackson M.L.
        • et al.
        Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study.
        J Am Geriatr Soc. 2011; 59: 1899-1907
        • Almirall J.
        • Bolibar I.
        • Serra-Prat M.
        • et al.
        New evidence of risk factors for community-acquired pneumonia: a population-based study.
        Eur Respir J. 2008; 31: 1274-1284
        • Bateson A.N.
        Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.
        Curr Pharm Des. 2002; 8: 5-21
        • Beaupre A.
        • Soucy R.
        • Phillips R.
        • Bourgouin J.
        Respiratory center output following zopiclone or diazepam administration in patients with pulmonary disease.
        Respiration. 1988; 54: 235-240
        • Zacharias M.
        • Hunter K.M.
        • Parkinson R.
        Respiratory effects of intravenous midazolam.
        N Z Dent J. 1996; 92: 76-79
        • Girault C.
        • Muir J.F.
        • Mihaltan F.
        • et al.
        Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD.
        Chest. 1996; 110: 1203-1211
        • Murciano D.
        • Aubier M.
        • Palacios S.
        • Pariente R.
        Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD).
        Chest. 1990; 97: 51S-52S
        • Wu C.S.
        • Shau W.Y.
        • Chan H.Y.
        • Lai M.S.
        Persistence of antidepressant treatment for depressive disorder in Taiwan.
        Gen Hosp Psychiatry. 2013; 35: 279-285